
    
      PROTOCOL OUTLINE: The patient receives subcutaneous recombinant human insulin-like growth
      factor 1 daily for 7 months. The dose is adjusted according to the serum hormone level and
      biological markers of bone turnover.

      Concurrent therapy includes a metabolic diet, calcium citrate, and estradiol.
    
  